Dr. Karin Hehenberger is an experienced life sciences executive. She founded Lyfebulb in January 2014, with a mission to improve the quality of life for people living with chronic disease. Karin holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and conducted her post-doctoral work as a JDRF fellow at the Joslin Diabetes Center at Harvard Medical School. She has held leadership positions at Johnson & Johnson, Eyetech pharmaceuticals and Coronado biosciences, as well as on the investment side of healthcare at both private and public multi-billion dollar funds. She is a Senior Advisor, Biotechnology and Medical Innovation, for the Department of Endocrinology and Surgery at the Karolinska Institute, and sits on the board of the Rolf Luft Diabetes Research Foundation and was previously a board member of the Lighthouse Guild foundation. She is a Swedish citizen, but based in New York City.